A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma

David A. Bonda Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology

https://orcid.org/0000-0003-0773-1829

Ying Huanga Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology

Beth A. Christiana Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology

Samantha Jaglowskia Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology

https://orcid.org/0000-0002-4335-2554

Don Bensona Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology

Lapo Alinaria Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology

Robert A. Baiocchia Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology

Jonathon B. Cohenb Emory University, Atlanta, GA, USA

Kristie A. Bluma Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical Oncology;b Emory University, Atlanta, GA, USA

Kami J. Maddocksa Department of Internal Medicine, Division of Hematology b. Department of Hematology and Medical OncologyCorrespondence[email protected]

show all

Click to increase image sizeClick to decrease image size

Disclosure statement

DB has consulted for Sea Gen and Kite/Gilead. BC has received research funding from Acerta, Celgene, Genentech, Triphase, MorphoSys, and Merck and has consulted for Verastem, Sea Gen, Genentech, and Astra Zeneca. SJ has received research funding from Gilead, Novartis, and Unum and has consulted for Bristol Myers Squibb, Gilead, and Novartis. JC has received research funding from Janssen, Novartis, TG Therapeutics, Astra Zeneca, Genentech, and Gilead and has consulted for Genentech, Bristol Myers Squibb, Novartis, Astra Zeneca, Loxo, and Sea Gen. KM has received research funding from Novartis, Bristol Myers Squibb, and Pharmacyclics and has consulted for Morphosys, ADC Therapeutics, Astra Zeneca, Beigene, Celgene, Gilead, and Sea Gen. All other authors declare no competing interests.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma

Information for

Open access

Opportunities

Help and information

A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature